Supplementary Results

Simulation case-control data only
To evaluate the performance of the approximate CC model for different parameter values, we simulated a single CC sample with either one or two variant/annotation classes. We tested sample sizes ranging from that of the available data, 1,092 each cases and controls (ASD), and 3,157 cases and controls (SCZ), to larger sample sizes of 10,000 cases and controls, and 20,000 cases and controls. Overall, high correlations (∼ 1) between estimated and simulated parameter values indicate little bias in inference based on CC data (Figure S5 and S7) . Slight over estimation was observed for the sample size of 1092, especially for risk-gene proportions.
An additional analysis was carried out to assess the performance of specific simulated values. Correlations were calculated for each mean RR and π value. For one CC class, mean RRs were estimated well by the model with correlations ∼ 1 ( Figure S6 ). However, the proportion of risk genes was affected by mean RRs. They were estimated well when mean RRs were between 1.5 and 3.5, but underestimated with smaller mean RRs and slightly overestimated with larger mean RRs (Figure S6 ). For two CC classes, high correlations (≥ 0.97) between simulated and estimated values were seen for all parameters. In addition, small mean RRs of a given class did not directly affect the estimated values of proportions of risk genes (Figure S8) .
The issue of poor estimation for one class, but good estimation for > one class was expected. This was an advantage of using multiple classes compared to using only one class in the estimation process when the clustering signal was not very strong. Small mean RRs could result in difficulties in the calculation process to differentiate between a risk gene (mean RR > 1) and a non-risk gene (mean RR ∼ 1). If one class was used then many risk genes would be considered to be non-risk genes. If more than one class was used, such risk genes would be assigned as genuine risk genes due to the information available from other classes.
Comparing genetic parameters between extTADA and TADA
We also applied the current version of TADA to SCZ and four NDDs. Estimated risk-gene proportions (π) were smaller than those of extTADA, except for DD (Table 1 .4). For SCZ, EPI, DD, these estimates were within the CIs of extTADA. However, estimated π values were too small for ASD and ID, only 1.8% and 1% respectively. ASD'sπ was also much smaller than the result reported by TADA using a smaller data set (He et al., 2013) . TADA mean RR estimation (γ) did not converge for MiD, silentCFPk de novo mutations as well as the third CC population sample for SCZ. This might be because the genetic signal of these categories was not very strong. For four NDDs, estimated mean RRs (γ) were higher than those of extTADA, although mostly within the extTADA credible intervals. We would expect these differences between two pipelines because we only used variant-count information to input for TADA, and only LoF de novo mutations to estimate π; if more prior information were used, the TADA results might converge to inside CIs of extTADA. Importantly, we note that the parameter estimation procedure for TADA does not provide confidence intervals, which is a main motivating rationale for the development of extTADA. Finally, the differences in estimated parameters yield different, although overall strongly correlated, gene-level association results ( Figure S4 ).
Supplementary methods
1.2.1 Analysis of SCZ data 1.2.1.1 Obtaining non-heterogeneous population samples for casecontrol data of SCZ
The case-control data sets were divided into three big populations: Finland, United Kingdom and Sweden. For the Sweden population, this was a large data set and was also sequenced at different centers (Genovese et al., 2016) , therefore we divided this population as follows.
A simple combination between a clustering process using a multivariate normal mixture model and a data analyzing strategy using linear and generalized linear models was used to divide the Sweden data into non-heterogeneous populations. Genovese et al. (2016) recently analyzed all case-control data sets by adjusting for multiple covariates: genotype gender of individuals (SEX), 20 principal components (PCs), year of birth of individuals (BIRTH), Aligent kit used in wet-labs (KIT) by using linear regression and generalized linear regression models as in Equation 1. They reported significant results for NoExAC LoF and MiD variants; therefore, this information was used in this step. We defined homogeneous populations as populations which were not much affected by the covariates. Thus, for the populations, analyzing results using Equation 1 (adjusting covariates) would not be much different from those results using Equation 2 (not adjusting covariates). The mclust package Version 5.2 (Fraley and Raftery, 1999) which uses a multivariate normal mixture model was used to divide 11,161 samples (4,929 cases and 6,232 controls) into different groups. To see all situations of the grouping process, we used mclust with three strategies on 11,161 samples: grouping all 20 PCs, grouping all 20 PCs and total counts, and grouping only the first three PCs. The number of groups were set between 2 and 6. For each clustering time, Equation 1 and 2 were used to calculate p values for each variant category of each group from the clustering results (p1 and p2 respectively); then, Spearman correlation (Spearman, 1904) between pvalue results from the two Equations (cPvalue) was calculated. Next, to filter reliable results from the clustering process, we set criteria:
• cPvalue ≥ 0.85 and p-values for NoExAC ≤ 0.005.
• Ratio p1/p2 from Equation 1 and 2 had to between 0.1 and 1.
From results satisfied the above criteria, we manually chose groups which had similar results between Equation 2 and 1. logit(P (SCZ = 1)) ∼ count + countAll + sex + birth + kit + (1)
For the data from the UK10K project (Singh et al., 2016) , we divided the data into two separate populations England and Finland, and tested NoExAC variants in these populations by calculating sample-size-adjusted ratios between cases and controls. The ratios were 0.91 and 0.95 for the UK data. Regarding the Finland data, the ratio for MiD variants was only 0.41 which were extremely low. This could be a special case for the population or might be because of other technical reasons. We did not use this population in the next stage because it showed a different trend with other populations.
extTADA pipeline: extended transmission (case-control) and de novo analysis
This section describes more details the pipeline.
1.2.2.1 extTADA for one de novo population and one case/control population extTADA is summarized in Table S3 and Figure S2 . There, x dn ∼ P ois(2N d µ, γ dn ), x ca ∼ P ois(qN 1 γ cc ), x cn ∼ P ois(qN 0 ), and γ dn ∼ Gamma(γ dn β dn , β dn ), γ cc ∼ Gamma(γ cc β cc , β cc ), q ∼ Gamma(ρ, ν). Let K be the number of categories (e.g., LoF, MiD), and x i = (x i1 , .., x iK ) be the vector of counts at the i th given gene. The Bayes Factor for each j th category to test two hypotheses: H 0 : γ = 1 versus H 1 : γ = 1 was:
B ij = P (xij |H1) P (xij |H0) = P (xij |γ,q)P (q|H1)P (γ|H1)dqdγ P (xij |γ,q)P (q|H0)P (γ|H0)dqdγ Because γ = 1f or H 0 = P (xij |γ,q)P (q|H1)P (γ|H1)dqdγ P (xij |q)P (q|H0)dq
In Equation 3, x ij = x dn for de novo data and x ij = (x ca , x cn ) for casecontrol data. In addition, the integral over q was not applicable for de novo data because there is no q parameter for de novo data.
As in He et al. (2013) , the BF for the i th gene combining all categories is:
To calculate BFs, hyper parameters in Table S3 need to be inferred. Let φ 1j and φ 0j be hyper-parameters for H 1 and H 0 respectively. A mixture model of the two hypotheses was used to infer parameters using information across the number of tested genes (m) as:
Equation 5 was calculated across categories as in Equation 4. We used the same approach for the analysis of multiple population samples. Let N dn pop , Cdn and N cc pop , Ccc be the number of populations, categories for de novo and case-control data respectively. The total Bayes Factor of a given gene was the product of Bayes Factors of all populations as in the main text, and all hyper parameters were estimated using Equation 2 in the main text.
The hyper-parameters φ 1j = (γ j(dn) , γ j(cc) , β j(dn) , β j(cc) , ρ j , ν j ) were estimated using a Hamiltonian Monte Carlo (HMC) Markov chain Monte Carlo (MCMC) method implemented in the rstan package (Carpenter et al., 2015; R Core Team, 2016) . However, the model was first simplified by removing q (see below).
Simplified approximate case-control model
For case-control (transmitted) data, q ∼ Gamma(ρ, ν), and hyper-parameters ρ and ν controlled the mean and dispersion of q; therefore, as in the previous studies (He et al., 2013; De Rubeis et al., 2014) , ν was heuristically chosen (200 was used in all analyses) and ρ ν = the mean frequency across genes in both cases and controls.
We simplified the case-control model by expressing it as P (x ca , x cn |H j ) = P (x ca |x ca + x cn , H j )P (x ca + x cn |H j )
Because x ca ∼ P ois(N 1 qγ cc ) and x cn ∼ P ois(N 0 q), assuming that x ca and x cn were independent, the case data could be modeled as:
x ca |x ca + x cn , H j ∼ Binomial(x ca + x cn , θ|H j ) with θ|H 1 =
N1γcc
N1γcc+N0 and θ|H 0 =
N1 N1+N0
The marginal likelihood was P (x ca |x ca + x cn , H j ) = P (x ca |x ca + x cn , γ cc , H j )P (γ cc |H j )dγ cc Based on simulation results, the first part P (x ca |x ca + x cn , H j ) can be used to infer mean RRs (γ cc ); therefore only this part was used in the extTADA estimation process. However, to calculate Bayes Factors, we used full casecontrol models. We changed the order of integrals.
Control of an implied proportion of protective variants using the relative risk dispersion hyper-parameter
Ifγ and β were small then we could see a high proportion of protective variants whenγ is not large. Although this might be of biological interest, it is not currently accounted for in the model. To control the proportion of protective variants, we tested the relationship between β andγ in determining Gamma(γ dn β dn , β dn ). We set this proportion very low (2%) (Figure S3 ) and built a nonlinear relationship β = e a * γ b +c . The function nls in R was used to estimate a, b and c, as 6.77, −1.79 and −0.22 respectively.
Calculate Bayes Factor for case/control data
At a given gene, Bayes Factor for each class was calculated as BF = P (x1,x0|H1) P (x1,x0|H0) . The probability for each model (H j , j = 0, 1) was calculated in order to rely only γ parameters as follows.
P (x ca , x cn |H j ) = P (x cn |H j )P (x ca |x cn , H j )
• The first part P (x cn |H j ) was the same as De Rubeis et al. (2014):
P (x cn |H j ) = P (x cn |q, H j )P (q|ρ, ν, H j )dq = N egBin(x cn |ρ,
• The second part:
P (x ca |H j , x cn ) = P (x ca |q, γ cc )P (q|H j , x cn )P (γ cc |H j )dqdγ cc = [P (x ca |q, γ cc )P (q|H j , x cn )dq] P (γ cc |H j )dγ cc = N egBin(x ca |ρ + x cn ,
N0+ν
N1γcc+N0+ν )P (γ cc |H j )dγ cc
To identify the lower and upper limits of γ CC for the integral, we randomly sampled 10,000 times values from the Gamma(γ cc * β cc , β cc ) and used the minimum and maximum values for the lower and upper limits respectively.
Infer parameters using MCMC results
The rstan package (Carpenter et al., 2015) was used to run MCMC processes. For simulation data, 5,000 times and a single chain were used. For real data, 20,000 times and three independent chains were used. In addition, for SCZ data we used two steps to obtain final results. Firstly, 10,000 times were run to obtain parameters. After that, we calculated β values from estimated mean RRs as the Equation described in Table S3 . Finally, extTADA was re-run 20,000 times on the SCZ data with calculated β values set as constants to re-estimate mean RRs and the proportions of risk genes. For each MCMC process, a burning period = a half of total running times was used to assure that chains did not rely on their initial values. For example, we ran and removed 2,500 burning times before the 5,000 running times for simulation data.
We just chose 1,000 samples of each chain from MCMC results to do further analyses. For example, with a chain with 20,000 run times, the step to obtain a sample was 20 run times. For all estimated parameters from MCMC chains, the convergence of each parameter was diagnosed using the estimated potential scale reduction statistic (R) introduced in Stan (Carpenter et al., 2015) . To produce heatmap plots, modes as well as the credible intervals (CIs) of estimated parameters, the Locfit (Loader, 2007) was used. The mode values were used as our estimated values for other calculations. Figure S1 : Workflow of data analysis. Figure S2 : Comparison between TADA and extTADA. They both use the same model for de novo data (x dn and case/control (x ca , x cn ) data. extTADA combines all categories to obtain parameters and their credible intervals while TADA is based on LoF mutations. extTADA uses an approximate model for case-control data, and constrains β andγ in the estimation process. extTADA is designed to work for multiple populations. TADA can be used inside extTADA.
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extTADA q−value TADA q−value500 600 700 800 900 1000 500 600 700 800 900 1000 500 600 700 800 900 1000 500 600 700 800 900 1000 500 600 700 800 900 1000 500 600 700 800 900 1000 500 600 700 800 900 1000 Table S12 : SCZ genetic parameters using all variants in and not in ExAC database (InExAC + NoExAC). Table S20 : Enrichment of gene sets from different databases with SCZ genes from extTADA results. These p values were obtained by 10,000,000 simulations, and then adjusted by using the method of Benjamini and Hochberg (1995) . Table S24 : Enrichment results of GeNets. These are enrichment results of 6 communities obtained from GeNets.
